Perlecan therapy for white matter and cognitive impairment in closed head injury with long-term dysfunction (CHILD)

Perlecan 疗法治疗伴有长期功能障碍的闭合性颅脑损伤(儿童)的白质和认知障碍

基本信息

  • 批准号:
    10019126
  • 负责人:
  • 金额:
    $ 37.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-12-01 至 2022-04-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY / ABSTRACT Juvenile traumatic brain injury, even when in the most commonly occurring mild form (juvenile mild TBI, jmTBI), is a major public health issue that is associated with significant long-term morbidity and is a risk factor for cognitive decline. To date, very little is known about the pathological processes during the first week after jmTBI as well as their long-term potential as vascular contributions to cognitive impairment and dementia (VCID). It is critical to have a better understanding of the long-term changes in order to accurately develop new treatments to minimize or prevent VCID. We previously demonstrated long-term grey matter changes in the neurovascular unit (NVU), blood-brain barrier (BBB) and brain extracellular matrix proteins in experimental moderate/severe juvenile-TBI. However, as long-term white matter (WM) changes also occur and have been implicated in accelerated cognitive decline in clinical and pre-clinical studies, we hypothesize that early post- jmTBI vascular dysfunction with degradation of extracellular matrix (ECM) proteins significantly contributes to long-term WM injury and VCID. Intriguingly, in various models of WM injury and VCID, a significant acute increase in WM expression of the vascular ECM heparan sulfate proteoglycan, perlecan, as well as its neuroprotective and angiogenic C-terminal protein fragment domain V (DV), is observed. We hypothesize that in the context of vascular dysfunction and ECM degradation, DV is acutely generated in WM after jmTBI and plays a significant, potentially beneficial role to WM's response to- and long-term cognitive consequences of jmTBI that could be therapeutically exploited. To investigate this hypothesis, we have developed a novel mouse jmTBI model of Closed Head Injury with Long- term Dysfunctions (named CHILD) to investigate early WM vascular changes as a model of VCID. Specifically, we propose to determine the role of the extracellular matrix protein perlecan DV in WM neurovascular unit changes and long-term cognitive decline after jmTBI as a model of VCID, and to determine the therapeutic potential and endothelial cell mechanism of action of recombinant domain V in jmTBI as a model of VCID.
项目总结/摘要 青少年创伤性脑损伤,即使是最常见的轻度形式(青少年轻度TBI, jmTBI)是一个重大的公共卫生问题,与显著的长期发病率相关,是一个危险因素 认知能力下降。到目前为止,对第一周的病理过程知之甚少。 jmTBI及其作为血管对认知障碍和痴呆的长期贡献的潜力 (VCID)。更好地了解长期变化,以便准确地开发新的 治疗以减少或预防VCID。我们以前证明了在大脑中的长期灰质变化, 神经血管单位(NVU)、血脑屏障(BBB)和脑细胞外基质蛋白的表达 中度/重度青少年TBI。然而,由于长期的白色物质(WM)变化也会发生, 在临床和临床前研究中,我们推测, 伴随细胞外基质(ECM)蛋白降解的jmTBI血管功能障碍显著有助于 长期WM损伤和VCID。有趣的是,在WM损伤和VCID的各种模型中, 血管ECM硫酸乙酰肝素蛋白聚糖、串珠素及其受体的WM表达增加, 神经保护和血管生成C-末端蛋白片段结构域V(DV)。我们假设 在血管功能障碍和ECM降解的背景下,DV在jmTBI后的WM中急性产生, 对WM对以下认知后果的反应和长期认知后果起着重要的、潜在的有益作用: jmTBI可以用于治疗。为了研究这一假设,我们开发了一种新的 小鼠jmTBI模型的闭合性头部损伤与长期功能障碍(命名为CHILD), WM血管改变作为VCID模型。具体来说,我们建议确定细胞外的作用, 基质蛋白串珠素DV在WM神经血管单位的变化和jmTBI后长期认知功能下降中的作用 模型的VCID,并确定治疗潜力和内皮细胞的作用机制, 在jmTBI中的重组结构域V作为VCID的模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jerome Badaut其他文献

Jerome Badaut的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jerome Badaut', 18)}}的其他基金

Caveolin-1 contributes to the long-term function and structure of the neurovascular unit after juvenile concussion
Caveolin-1 有助于青少年脑震荡后神经血管单元的长期功能和结构
  • 批准号:
    10452647
  • 财政年份:
    2021
  • 资助金额:
    $ 37.6万
  • 项目类别:
Caveolin-1 contributes to the long-term function and structure of the neurovascular unit after juvenile concussion
Caveolin-1 有助于青少年脑震荡后神经血管单元的长期功能和结构
  • 批准号:
    10670316
  • 财政年份:
    2021
  • 资助金额:
    $ 37.6万
  • 项目类别:
Caveolin-1 contributes to the long-term function and structure of the neurovascular unit after juvenile concussion
Caveolin-1 有助于青少年脑震荡后神经血管单元的长期功能和结构
  • 批准号:
    10299440
  • 财政年份:
    2021
  • 资助金额:
    $ 37.6万
  • 项目类别:
AQP4 and JNK Inhibition Together Reduce Edema and Excitotoxic Injury in jTBI
AQP4 和 JNK 抑制共同减少 jTBI 中的水肿和兴奋性毒性损伤
  • 批准号:
    8117743
  • 财政年份:
    2009
  • 资助金额:
    $ 37.6万
  • 项目类别:
AQP4 and JNK Inhibition Together Reduce Edema and Excitotoxic Injury in jTBI
AQP4 和 JNK 抑制共同减少 jTBI 中的水肿和兴奋性毒性损伤
  • 批准号:
    8307344
  • 财政年份:
    2009
  • 资助金额:
    $ 37.6万
  • 项目类别:
AQP4 and JNK Inhibition Together Reduce Edema and Excitotoxic Injury in jTBI
AQP4 和 JNK 抑制共同减少 jTBI 中的水肿和兴奋性毒性损伤
  • 批准号:
    7743132
  • 财政年份:
    2009
  • 资助金额:
    $ 37.6万
  • 项目类别:
AQP4 and JNK Inhibition Together Reduce Edema and Excitotoxic Injury in jTBI
AQP4 和 JNK 抑制共同减少 jTBI 中的水肿和兴奋性毒性损伤
  • 批准号:
    7878704
  • 财政年份:
    2009
  • 资助金额:
    $ 37.6万
  • 项目类别:
Caveolin 1 Role in Hemorrhagic Injuries
Caveolin 1 在出血性损伤中的作用
  • 批准号:
    8661426
  • 财政年份:
  • 资助金额:
    $ 37.6万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 37.6万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了